Journal article
Clinical Outcome of Hyperuricemia in IgA Nephropathy: A Retrospective Cohort Study and Randomized Controlled Trial
Kidney & blood pressure research, Vol.35(3), pp.153-160
01/01/2012
DOI: 10.1159/000331453
PMCID: PMC3242707
PMID: 22116196
Abstract
Background: Hyperuricemia is an independent risk factor for renal progression in IgA nephropathy (IgAN). However, no study has evaluated the effect of allopurinol on the clinical outcome in hyperuricemic IgAN. Methods: First, a retrospective cohort study of 353 IgAN patients was conducted to explore the relationship between uric acid (UA) and the progression of renal disease over a mean period of 5 years. Then, 40 hyperuricemic IgAN patients were randomized to receive allopurinol (100-300 mg/day) or usual therapy for 6 months. The study outcomes were renal disease progression and/or blood pressure. Results: Hyperuricemia independently predicted renal survival at 1, 3, and 5 years after adjustment for different baseline estimated glomerular filtration rates. In the randomized controlled trial, allopurinol did not significantly alter renal progression or proteinuria. The antihypertensive drug dosage was reduced in 7 of 9 cases with hypertension in the allopurinol group compared to 0 of 9 cases in the control group (p < 0.01). UA levels correlated with mean arterial pressure in normotensive patients (r = 0.388, p < 0.001). Conclusion: Hyperuricemia predicts the progression of IgAN independently of baseline estimated glomerular filtration rate. Allopurinol may improve the control of blood pressure. Further studies are required to explore the effects of lowering UA on renal protection in IgAN. Copyright (C) 2011 S. Karger AG, Basel
Details
- Title: Subtitle
- Clinical Outcome of Hyperuricemia in IgA Nephropathy: A Retrospective Cohort Study and Randomized Controlled Trial
- Creators
- Yongjun Shi - The First Affiliated Hospital, Sun Yat-sen UniversityWei Chen - Sun Yat-sen UniversityDiana Jalal - University of Colorado DenverZhibin Li - Sun Yat-sen UniversityWenfang Chen - Sun Yat-sen UniversityHaiping Mao - Sun Yat-sen UniversityQiongqiong Yang - Sun Yat-sen UniversityRichard J. Johnson - University of Colorado DenverXueqing Yu - Sun Yat-sen University
- Resource Type
- Journal article
- Publication Details
- Kidney & blood pressure research, Vol.35(3), pp.153-160
- Publisher
- Karger
- DOI
- 10.1159/000331453
- PMID
- 22116196
- PMCID
- PMC3242707
- ISSN
- 1420-4096
- eISSN
- 1423-0143
- Number of pages
- 8
- Grant note
- 6021368 / Guangdong Natural Science Foundation; National Natural Science Foundation of Guangdong Province 2010-76 / Guangdong province university academic and discipline development R01DK052121 / NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) R01HL068607 / NATIONAL HEART, LUNG, AND BLOOD INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI) Sun Yat-sen University 2006A36001002; 2005B30701002 / Scientific and Technologic Committee of Guangdong Province A2005189 / Guangdong Province Health Office HL-68607; DK-52121 / NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA ISN 2011CB50400050 / 973 project; National Basic Research Program of China
- Language
- English
- Date published
- 01/01/2012
- Academic Unit
- Nephrology; Internal Medicine
- Record Identifier
- 9984360052202771
Metrics
11 Record Views